Atypical Apocrine Metaplasia: Clinical Significance and Management
Atypical apocrine metaplasia (AAM) on breast biopsy requires surgical excision due to a documented upgrade rate to malignancy, particularly when associated with sclerosing lesions (atypical apocrine adenosis), though the absolute risk varies based on patient age and lesion characteristics.
Understanding the Lesion
Atypical apocrine metaplasia represents apocrine cells with cytologic atypia—defined as at least threefold variation in nuclear size with enlarged nucleoli—occurring in breast tissue 1, 2. This is distinct from simple apocrine metaplasia (a common benign finding in women over 25) because of the nuclear abnormalities present.
Risk Stratification
The cancer risk associated with AAM depends critically on:
- Age: Women over 60 years have a substantially elevated risk (relative risk 14,95% CI 4.1-48) compared to younger women 3
- Lesion type: Atypical apocrine adenosis (AAA)—when atypia occurs within sclerosing adenosis—carries a 20% upgrade rate to DCIS or invasive carcinoma at excision 4
- Isolated AAM: When AAM occurs without sclerosing features, the upgrade risk appears lower, though data are limited
Recommended Management Algorithm
For Atypical Apocrine Adenosis (AAA):
- Surgical excision is mandatory given the 20% upgrade rate 4
- All four malignancies in one series presented as masses on ultrasound (irregular or circumscribed), with three having associated calcifications 4
For Isolated Atypical Apocrine Metaplasia:
- Surgical excision is recommended, particularly in women over 60 years
- In younger women (<60 years), the risk appears lower, but excision remains prudent given diagnostic uncertainty 3
If excision shows only AAM without upgrade:
- Long-term surveillance is essential, as carcinoma developed after a mean of 5.6 years in one cohort 3
- The relative risk of developing breast carcinoma is 5.5 overall (95% CI 1.9-16) 3
Imaging Correlation
When AAM/AAA is diagnosed on core biopsy, review the imaging characteristics:
- Irregular or circumscribed masses on ultrasound with or without calcifications warrant particular concern 4
- Amorphous or coarse heterogeneous calcifications were present in malignancies that upgraded 4
- T2 hyperintense foci on MRI may indicate associated apocrine cysts 5
Critical Pitfalls to Avoid
- Do not dismiss AAM as benign apocrine metaplasia—the nuclear atypia fundamentally changes the clinical significance
- Do not rely on short-term follow-up alone—excision is needed to exclude concurrent DCIS or invasive carcinoma
- Age matters significantly—women over 60 have markedly higher risk and require particularly close attention 3
- Distinguish from apocrine DCIS—if architectural features of DCIS are present, this is not AAM but rather in situ carcinoma requiring different management 2
Long-Term Surveillance
Even after benign excision, continued clinical observation is advisable given the elevated long-term risk 3, 6. While one older study with 35-month follow-up showed no cancers developing 6, a longer study (8.7 years) demonstrated delayed carcinoma development 3, emphasizing the need for ongoing surveillance rather than discharge after negative excision.